ArticleMetabolism: clinical and experimental2021
Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1.
Article in Metabolism: clinical and experimental, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Review
- Diminished CEACAM1 level plays a critical role in age-related hepatic fibrosis.Mechanisms of ageing and development · 2025Article
- Regulation of lipid storage and inflammation in the liver by CEACAM1.European journal of clinical investigation · 2024Review
- Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1.Metabolism and target organ damage · 2024Article
- Current investigation of carcinoembryonic antigen cell adhesion molecule (CEACAM) biology summary of the 32nd CEA symposium: 20-23 September 2024. Würzburg, Germany.European journal of clinical investigation · 2024Article
- Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation.Molecular metabolism · 2024Article
- CEACAM1: Shielding the liver against fibrosis.European journal of clinical investigation · 2024Article
- Loss of CEACAM1 in hepatocytes causes hepatic fibrosis.European journal of clinical investigation · 2024Article
- Hepatic insulin receptor: new views on the mechanisms of liver disease.Metabolism: clinical and experimental · 2023Review
- Loss of CEACAM1 in endothelial cells causes hepatic fibrosis.Metabolism: clinical and experimental · 2023Article
- Regulation of Insulin Clearance by Non-Esterified Fatty Acids.Biomedicines · 2022Review
- Reversal of obesity development in Ceacam1Obesity (Silver Spring, Md.) · 2022Article
- Aortic Fibrosis in Insulin-Sensitive Mice with Endothelial Cell-Specific Deletion ofInternational journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveNAFLD is a complex disease marked by cellular abnormalities leading to NASH. NAFLD patients manifest low hepatic levels of CEACAM1, a promoter of insulin clearance. Consistently, Cc1
methods3-Month-old mice were fed a high-fat diet for 3-5 months, and metabolic and histopathological analysis were conducted to evaluate their NASH phenotype.
resultsReconstituting CEACAM1 to Cc1
conclusionsRestored metabolic and histopathological phenotype of HF-fed Cc1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.